Market Currents
Leerink says Jazz Pharmaceuticals (JAZZ -0.5%) shares don't reflect the positive aspects of the...
-
Wednesday, June 20, 2012, 12:45 PM ETLeerink says Jazz Pharmaceuticals (JAZZ -0.5%) shares don't reflect the positive aspects of the EUSA acquisition. In particular, Leerink says that the stock hasn't adequately priced in the true earnings potential from the deal. The firm sees opportunity for investors and reiterates an Outperform rating on shares with a $68 price target.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
